-
公开(公告)号：US20220193022A1
公开(公告)日：2022-06-23
申请号：US17388361
申请日：2021-07-29
发明人： Keith Chan , Winston Town
IPC分类号： A61K31/295 , A61K9/14 , A61K31/555 , A61K33/26
摘要： The present invention discloses pharmaceutical-grade ferric organic compounds having enhanced dissolution rate. These ferric organic compounds, including but are not limited to ferric citrate, are useful for treating chronic kidney disease.
-
12.发明申请公开(公告)号：US20190269722A1
公开(公告)日：2019-09-05
申请号：US16352455
申请日：2019-03-13
IPC分类号： A61K33/26 , C07C59/265 , A61K31/295 , C07C51/41
摘要： The present invention discloses pharmaceutical-grade ferric organic compounds, including ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. A manufacturing and quality control process for making a pharmaceutical-grade ferric citrate that consistently complies with the established Manufacture Release Specification is also disclosed. The pharmaceutical-grade ferric organic compounds are suitable for treating disorders characterized by elevated serum phosphate levels.
-
公开(公告)号：US20190055274A1
公开(公告)日：2019-02-21
申请号：US15918308
申请日：2018-03-12
IPC分类号： C07F15/02 , C07C51/41 , C07C59/265 , A61K31/295
摘要： The present invention discloses a novel form of ferric organic compounds, including a form of ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. The ferric organic compounds of the present invention can be delivered effectively by oral route with better delivery to treat patients suffering from hyperphosphatemia, metabolic acidosis and other disorders responsive to ferric organic compound therapy.
-
14.发明申请公开(公告)号：US20180214480A1
公开(公告)日：2018-08-02
申请号：US15699025
申请日：2017-09-08
IPC分类号： A61K33/26 , C07C51/41 , A61K31/295 , C07C59/265 , C07C55/10 , C07C59/255 , C07C53/08 , C07C59/245 , C07C57/15
CPC分类号： A61K33/26 , A61K31/295 , C07C51/412 , C07C51/418 , C07C59/265 , C07C55/10 , C07C59/255 , C07C53/08 , C07C59/245 , C07C57/15
摘要： The present invention discloses pharmaceutical-grade ferric organic compounds, including ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. A manufacturing and quality control process for making a pharmaceutical-grade ferric citrate that consistently complies with the established Manufacture Release Specification is also disclosed. The pharmaceutical-grade ferric organic compounds are suitable for treating disorders characterized by elevated serum phosphate levels.
-
15.发明申请PHARMACEUTICAL-GRADE FERRIC ORGANIC COMPOUNDS, USES THEREOF AND METHODS OF MAKING SAME 有权药用级有机化合物，其用途及其制备方法公开(公告)号：US20160095878A1
公开(公告)日：2016-04-07
申请号：US14701933
申请日：2015-05-01
IPC分类号： A61K33/26
CPC分类号： A61K33/26 , A61K31/295 , C07C51/412 , C07C51/418 , C07C59/265 , C07C55/10 , C07C59/255 , C07C53/08 , C07C59/245 , C07C57/15
摘要： The present invention discloses pharmaceutical-grade ferric organic compounds, including ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. A manufacturing and quality control process for making a pharmaceutical-grade ferric citrate that consistently complies with the established Manufacture Release Specification is also disclosed. The pharmaceutical-grade ferric organic compounds are suitable for treating disorders characterized by elevated serum phosphate levels.
摘要翻译： 本发明公开了包括柠檬酸铁在内的药物级三价铁有机化合物，其在较宽的pH范围内可溶，并且具有大的活性表面积。 还公开了制造和质量控制过程，用于制造符合既定制造版本规范的药用级柠檬酸铁。 药物级铁有机化合物适用于治疗以血清磷酸盐水平升高为特征的疾病。
-
16.发明授权Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same 有权药用级铁有机化合物，其用途及其制备方法公开(公告)号：US09050316B2
公开(公告)日：2015-06-09
申请号：US14306756
申请日：2014-06-17
IPC分类号： A61K31/295 , C07C59/265 , A61K33/26 , C07C51/41
CPC分类号： A61K33/26 , A61K31/295 , C07C51/412 , C07C51/418 , C07C59/265 , C07C55/10 , C07C59/255 , C07C53/08 , C07C59/245 , C07C57/15
摘要： The present invention discloses a pharmaceutical-grade ferric organic compounds, including ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. A manufacturing and quality control process for making a pharmaceutical-grade ferric citrate that consistently complies with the established Manufacture Release Specification is also disclosed. The pharmaceutical-grade ferric organic compounds are suitable for treating disorders characterized by elevated serum phosphate levels.
摘要翻译： 本发明公开了一种药物级三价铁的有机化合物，包括柠檬酸铁，其在较宽的pH范围内是可溶的，并且具有大的活性表面积。 还公开了制造和质量控制过程，用于制造符合既定制造版本规范的药用级柠檬酸铁。 药物级铁有机化合物适用于治疗以血清磷酸盐水平升高为特征的疾病。
-
公开(公告)号：US08901349B2
公开(公告)日：2014-12-02
申请号：US14011325
申请日：2013-08-27
IPC分类号： C07F15/02 , C07C59/265 , A61K31/295 , C07C51/41
CPC分类号： C07F15/025 , A61K31/295 , C07C51/41 , C07C51/412 , C07C51/418 , C07C59/265 , C07F15/02 , C07C55/10 , C07C59/255 , C07C53/08 , C07C59/245 , C07C57/15
摘要： The present invention discloses a novel form of ferric organic compounds, including a form of ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. The ferric organic compounds of the present invention can be delivered effectively by oral route with better delivery to treat patients suffering from hyperphosphatemia, metabolic acidosis and other disorders responsive to ferric organic compound therapy.
-
公开(公告)号：US08609896B2
公开(公告)日：2013-12-17
申请号：US13672900
申请日：2012-11-09
IPC分类号： C07C63/36
CPC分类号： C07F15/025 , A61K31/295 , C07C51/41 , C07C51/412 , C07C51/418 , C07C59/265 , C07F15/02 , C07C55/10 , C07C59/255 , C07C53/08 , C07C59/245 , C07C57/15
摘要： The present invention discloses a novel form of ferric organic compounds, including a form of ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. The ferric organic compounds of the present invention can be delivered effectively by oral route with better delivery to treat patients suffering from hyperphosphatemia, metabolic acidosis and other disorders responsive to ferric organic compound therapy.
摘要翻译： 本发明公开了一种新型的三价铁有机化合物，其包括柠檬酸铁的形式，其可在较宽的pH范围内溶解并具有大的活性表面积。 本发明的铁有机化合物可以通过口服途径有效地递送，具有更好的输送以治疗患有高磷酸盐血症，代谢性酸中毒和对三价铁有机化合物治疗有反应的其它病症的患者。
-
公开(公告)号：US20180235923A1
公开(公告)日：2018-08-23
申请号：US15894544
申请日：2018-02-12
发明人： Keith CHAN , Winston Town , Shou Shan Chiang
IPC分类号： A61K31/295 , A61K33/26 , A61K9/14 , A61K31/555
CPC分类号： A61K31/295 , A61K9/143 , A61K31/555 , A61K33/26
摘要： The present invention provides methods of treating soft tissue calcification in a subject, comprising a step of administering to said subject an effective amount of ferric organic compound, such as ferric citrate. The claimed methods may prevent, reverse, delay or stabilize soft tissue calcification in a subject having chronic kidney disease. Affected soft tissue calcification includes soft tissue calcification in the joint, skin, eye, in cardiovascular system such as heart valve, myocardium, coronary arteries and arteriole, or in internal organs such as kidney and lung.
-
公开(公告)号：US09889113B2
公开(公告)日：2018-02-13
申请号：US15694876
申请日：2017-09-04
发明人： Keith Chan , Winston Town , Shou Shan Chiang
IPC分类号： A61K31/295 , A61K9/14 , A61K33/26 , A61K31/555
CPC分类号： A61K31/295 , A61K9/143 , A61K31/555 , A61K33/26
摘要： The present invention provides methods of treating soft tissue calcification in a subject, comprising a step of administering to said subject an effective amount of ferric organic compound, such as ferric citrate. The claimed methods may prevent, reverse, delay or stabilize soft tissue calcification in a subject having chronic kidney disease. Affected soft tissue calcification includes soft tissue calcification in the joint, skin, eye, in cardiovascular system such as heart valve, myocardium, coronary arteries and arteriole, or in internal organs such as kidney and lung.
-
-
-
-
-
-
-
-
-
搜索结果
32 条记录 (耗时 0.029 秒)
